Table 1.
Baseline characteristics
| Total cohort, n = 153 | ||
|---|---|---|
| Age (years) |
|
|
| Female gender | 50 (33) | |
| Body mass index (kg/m2) | 26.9 4.2 | |
| Permanent atrial fibrillation | 69 (45) | |
| Congestive heart failure | 27 (18) | |
| LVEF (%) | 60 (50–60) | |
| Hypertension | 125 (82) | |
| Diabetes mellitus | 26 (17) | |
| Previous stroke or TIA | 69 (45) | |
| Peripheral vascular disease | 65 (42) | |
| History of bleeding | 127 (83) | |
| Chronic kidney disease, Stage 3–5 | 11 (7) | |
| Creatinine (µmol/L) | 85 (72–103) | |
| CHA2DS2‐VASc score | 4.1 1.6 | |
| HAS‐BLED score | 3.8 1.0 | |
| Primary indication for LAAO | ||
| ICH | 63 (41) | |
| GI bleeding | 31 (20) | |
| Urogenital bleeding | 12 (7) | |
| Other spontaneous bleeding | 15 (10) | |
| Cerebral amyloid angiopathy | 10 (6) | |
| Stroke despite OAC | 9 (8) | |
| High bleeding risk | 13 (8) |
Note: Data are presented as mean ± SD, median (IQR), or frequency (%).
Abbreviations: GI, gastrointestinal; HAS‐BLEDICH, intracranial hemorrhage; LAAO, left atrial appendage occlusion; LVEF, left ventricular ejection fraction; OAC, oral anticoagulation; TIA, transient ischemic attack.